ClinicalTrials.gg
CompletedNCT00242333Updated May 16, 2006

A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD

A Phase 2 interventional study of AD 237 in COPD, sponsored by Sosei. Completed at 33 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2006-05-16.

Sponsored by Sosei · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
29th of 73
300 · median 152
Started
2005
the only one that year
Phase 2
19 of 73
none open now
Registered
1st of 73
by date

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 29th largest by enrollment, is the only one that started in 2005, is one of 19 in phase 2, and was the 1st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237 in patients with chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • COPD

Keywords

  • COPD
  • COAD
  • Chronic obstructive pulmonary disease
  • emphysema
  • chronic bronchitis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with , with symptoms of cough and chronic sputum production and/or dyspnea.
  • Post-bronchodilator at no more than 65% and at least 30% of the predicted normal value.
  • Pre-bronchodilator FEV1/FVC ratio of less than 70%.
  • Current or ex-smokers with a smoking history of at least 10 pack years.

Exclusion criteria

Exclusion Criteria:

  • History of asthma, atopy or allergic rhinitis.
  • Other serious respiratory or other medical conditions which may interfere with the outcome of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
300 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Pulmonary function

Secondary outcomes

  1. Pulmonary function

07

Study locations

33 sites
  • Specialized Hospital for Active Treatment Pneumophthysiatric Disease "Kudoglu"
    Plovdiv, 4000, Bulgaria
  • Regional Dispensary for Pulmonary Diseases Rousse
    Rousse, 7002, Bulgaria
  • 5-th Multiprofile Hospital for Active Treatment
    Sofia, 1233, Bulgaria
  • MHAT "Alexandrovska"
    Sofia, 1431, Bulgaria
  • Specialized Hospital for Active Treatment of Pulmonary Diseases "Sveta Sofia"
    Sofia, 1431, Bulgaria
  • Central Clinical Base - Medical Institute - Ministry of the Interior
    Sofia, 1606, Bulgaria
  • Military Medical Academy
    Sofia, 1606, Bulgaria
  • UMHAT "Stara Zagora" EAD
    Stara Zagora, 6003, Bulgaria
  • University Hospital
    Varna, 9010, Bulgaria
  • Tudogyintezete Nodradgardony
    Balassagyarmat, 2661, Hungary
  • III. district Outpatient Clinic
    Budapest, 1033, Hungary
  • Diagnostic Units Hungary Ltd
    Budapest, 1036, Hungary
  • Gyogyir XI. Kht.II. Tudogondozo Intezet
    Budapest, 1221, Hungary
  • Selye Janos Hospital
    Komarom, 2900, Hungary
  • Karolona Hospital
    Mosonmagyarovar, 9200, Hungary
  • Szabolcs Szatmar Bereg Megyei Josa Andras Korhaz
    Nyiregyhaza, 4400, Hungary
  • Fejer County Szent Gyorgy Hospital
    Szekesfehervar, 8001, Hungary
  • Vas County Markusovszky Hospital
    Szombathely, 9700, Hungary
  • Szpital Wojewodzki
    Bielsko-Biala, 43-316, Poland
  • 10 Wojskowy Szpital Kliniczny Z Poliklinika
    Bydgoszcz, 85-681, Poland
  • Samodzielny Publiczny Centralny Szpital Kliniczny SAM
    Katowice, 40-752, Poland
  • Specjalistyczny Osrodek Alergologiczny ALL-MED
    Krakow, 31-023, Poland
  • Barlicki University Hospital
    Lodz, 90-153, Poland
  • Szpital ZOZ
    Olawa, 55-200, Poland
  • Specjalistyczna Przychodnia Lekarska "Medikard"
    Plock, 09-402, Poland
  • Wielkopolskie Centrum Chorob Pluc I Gruzlicy
    Poznan, 60-569, Poland
  • Spitalul Clinic de Urgenta Floreasca
    Bucharest, 11641, Romania
  • Spitalul de Pneumo Ftiziologie "Sf. Stefan"
    Bucharest, 20122, Romania
  • Spitalul Clinic "Colentina"
    Bucharest, 20125, Romania
  • Institutul National de Boli Infectioase
    Bucharest, 21105, Romania
  • Spitalul Clinic de Boli Infectioase si Tropicale " Dr. Victor Babes "
    Bucharest, 30317, Romania
  • Institutul de Pneumologie " Marius Nasta "
    Bucharest, 50159, Romania
  • Spitalul Clinic de Urgenta Constanta
    Constanta, 900591, Romania
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00242333
Lead sponsor
Sosei
Collaborators
Novartis
First posted
Oct 20, 2005
Start date
Oct 2005
Last update
May 16, 2006

Study contacts

Robert G Tansley, MD
study director · Arakis Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion